Edgewise Therapeutics Sells Muscular Dystrophy Business and Sevasemten to Servier for up to $2.65 Billion

Source Summary

Wilson Sonsini Goodrich & Rosati has advised Edgewise Therapeutics on the transaction. Edgewise Therapeutics has announced the sale of sevasemten, an orally administered fast skeletal myosin [...]